Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 12/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.55 |
| ▸ | ESRRG | P62508 | 13/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | ESRRB | O95718 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5739854 | 1.00 | LMNA (0.56) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL5739858 | 1.00 | LMNA (0.56) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL6373600 | 0.95 | LMNA (0.65) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL6373608 | 0.95 | LMNA (0.65) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL6373604 | 0.95 | LMNA (0.65) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL6378869 | 0.93 | LMNA (0.54) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL6378878 | 0.93 | LMNA (0.54) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL5725431 | 0.91 | ESRRG (0.57) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL5725433 | 0.91 | ESRRG (0.57) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL5725712 | 0.91 | LMNA (0.59) | LMNAHTR6ESR1CYP19A1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD. | 2003-12-04 | — | — | US | claimed |
| US-6576645-B1 | Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect | HORMOS MEDICAL OY LTD (FI) | 2003-06-10 | — | — | US | claimed |
| EP-1705169-A2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | Hormos Medical Ltd. (FI) | 2006-09-27 | — | — | EP | disclosed |
| US-6875775-B2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD (FI) | 2005-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | ESR2, ESR1, GPER1 | LMNA 4585/4885HTR6 182/4885ESR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.